Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
Tevogen Bio Holdings Stock
Tevogen Bio Holdings Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Ryan H. Saadi
- Employees
- 18
- Market cap
- $29 M
- IPO
- 05/01/2022
- Web
- tevogen.com
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in…
Tevogen Bio Holdings stock: price history
1D
-0.1%
1W
+4.3%
1M
-9.4%
6M
-4.2%
YTD
-57.3%
1Y
-80.4%
2Y
-86.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~25% weaker price swings than usual
Ask the agents about Tevogen Bio Holdings
Analyst assessment of Tevogen Bio Holdings
0
STRONG BUY
0
BUY
1
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Hold
As of: 04/03/2026
Tevogen Bio Holdings stock metrics
P/E
-1.21
P/B
-3.05
EV/EBITDA
-1.39
RETURN ON EQUITY
64.8%
NET MARGIN
0.0%
DEBT/EQUITY
-0.34
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
25.5%
FLOAT SHARES
1,060,017
AVG. DAILY VOLUME (30D)
7,458
Insider transactions (SEC)
Desai Kirti
Saadi Ryan H.
Patton Curtis L.
Feike Jeffrey L.
Sordillo Victor J.
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Tevogen Bio Holdings stock
What does Tevogen Bio Holdings do?
Tevogen Bio Holdings Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Ryan H. Saadi, the company employs around 18 people.
The IPO was on 05/01/2022; the stock trades on NASDAQ under the ticker TVGN.
What do analysts say about Tevogen Bio Holdings stock?
1 analysts rate the stock, the consensus is Hold (as of 04/03/2026).
This is an external assessment, not a statement by Market Jury.
When does Tevogen Bio Holdings report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -25% stronger than usual.
Does Tevogen Bio Holdings pay a dividend?
No, Tevogen Bio Holdings currently does not pay a dividend.
Which stocks are comparable to Tevogen Bio Holdings?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tevogen Bio Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tevogen Bio Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.